Agenus Inc. (NASDAQ:AGEN - Get Free Report) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $3.30 and traded as high as $7.34. Agenus shares last traded at $7.06, with a volume of 6,804,832 shares traded.
Analyst Ratings Changes
A number of research firms recently commented on AGEN. B. Riley reiterated a "buy" rating on shares of Agenus in a research note on Monday, April 21st. HC Wainwright upgraded Agenus from a "neutral" rating to a "buy" rating and set a $25.00 target price for the company in a research note on Wednesday, June 4th. Robert W. Baird lifted their price target on Agenus from $4.00 to $6.00 and gave the company a "neutral" rating in a report on Wednesday, June 4th. Finally, Wall Street Zen raised Agenus from a "strong sell" rating to a "hold" rating in a report on Thursday, May 22nd. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $14.00.
Get Our Latest Stock Report on AGEN
Agenus Trading Down 8.9%
The stock's 50-day moving average is $4.45 and its 200-day moving average is $3.31. The company has a market cap of $170.53 million, a price-to-earnings ratio of -0.72 and a beta of 1.51.
Agenus (NASDAQ:AGEN - Get Free Report) last issued its earnings results on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share for the quarter, topping analysts' consensus estimates of ($1.61) by $0.58. The business had revenue of $24.07 million for the quarter, compared to the consensus estimate of $26.38 million. As a group, analysts predict that Agenus Inc. will post -12.55 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Corton Capital Inc. purchased a new position in shares of Agenus in the 4th quarter valued at about $36,000. Apollon Wealth Management LLC boosted its position in shares of Agenus by 25.0% in the first quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company's stock worth $38,000 after buying an additional 5,000 shares during the period. Virtu Financial LLC purchased a new position in Agenus in the fourth quarter valued at about $51,000. Acadian Asset Management LLC acquired a new stake in shares of Agenus during the 1st quarter worth approximately $58,000. Finally, Bank of Montreal Can acquired a new position in shares of Agenus during the 4th quarter valued at $69,000. 61.46% of the stock is currently owned by institutional investors.
Agenus Company Profile
(
Get Free Report)
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Featured Stories
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
